Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 18/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 18/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27787069 | 0.82 | NR1H2 (0.42) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1125194 | 0.82 | NR1H2 (0.62) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL35460 | 0.81 | NR1H2 (0.61) | NR1H2NR1H3HSD17B1HSD17B2 | |
| SCHEMBL35186 | 0.79 | NR1H2 (0.45) | NR1H2NR1H3HSD17B1HSD17B2 | |
| SCHEMBL35232 | 0.77 | NR1H2 (0.61) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL4012228 | 0.76 | SMN1; SMN2 (0.53) | NR1H2NR1H3 | |
| SCHEMBL35265 | 0.73 | NR1H2 (0.67) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1125069 | 0.72 | NR1H2 (0.59) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1124612 | 0.71 | NR1H2 (0.62) | NR1H2NR1H3 | |
| SCHEMBL1125248 | 0.71 | NR1H2 (0.62) | NR1H2NR1H3PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590948-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | Wyeth LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004748-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2074098-A2 | QUINOLINE COMPOUNDS | Wyeth (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008049047-A2 | QUINOLINE COMPOUNDS | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885PPARG 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.